GENE ONLINE|News &
Opinion
Blog

Amyotrophic Lateral Sclerosis
FDA Grants Biogen’s Ultra-Rare ALS Med Accelerated Approval
2023-04-26
Biogen’s Tofersen May Show Clinical Benefit in ALS Patients with Rare SOD1 Mutations
2023-03-21
Harvard’s Soft Robotic Wearable Device Helps ALS Patients Regain Arm Mobility
2023-02-09
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
Biogen’s ALS Drug Fails to Attain Primary Endpoint but Offers Hope With Secondary Outcomes
2021-10-18
Setting its Sights on Neurological Disorders, CRISPR Therapeutics Turns to an AAV Startup That Just Emerged Out of Stealth
2021-06-16
Lilly to Expand Foothold in the Billion-Dollar Autoimmune and Inflammatory Disease Market with this New Collaboration
2021-02-20
Brainstorm’s Stem Cell Therapy Flunks Phase 3 ALS Trial
2020-11-20
Scribe, Biogen Partner to Combat ALS using Nobel Prize-Winning CRISPR Technology
2020-10-08
R&D
Altering the Treatment Landscape of Neurodegenerative Diseases Using Antisense Oligonucleotides (ASOs)
2020-08-17
R&D
Merck and Yumanity Sign $500 Million Deal to Develop ALS and FTLD Treatments
2020-06-26
LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top